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Abstract
Activation of the P2X7 receptor by the extracellular damage-associated molecular pattern, adenosine 5′triphosphate (ATP), induces the shedding of cell surface molecules including the low-affinity IgE receptor,
CD23, from human leukocytes. A disintegrin and metalloprotease (ADAM) 10 mediates P2X7-induced
shedding of CD23 from multiple myeloma RPMI 8226 B cells; however, whether this process occurs in
primary B cells is unknown. The aim of the current study was to determine whether P2X7 activation
induces the rapid shedding of CD23 from primary human and murine B cells. Flow cytometric and ELISA
measurements showed that ATP treatment of human and murine B cells induced the rapid shedding of
CD23. Treatment of cells with the specific P2X7 antagonist, AZ10606120, near-completely impaired ATPinduced CD23 shedding from both human and murine B cells. ATP-induced CD23 shedding was also
impaired in B cells from P2X7 knockout mice. The absence of full-length, functional P2X7 in the P2X7
knockout mice was confirmed by immunoblotting of splenic cells, and by flow cytometric measurements
of ATP-induced YO-PRO-12+ uptake into splenic B and T cells. The broad-spectrum metalloprotease
antagonist, BB-94, and the ADAM10 antagonist, GI254023X, impaired P2X7-induced CD23 shedding from
both human and murine B cells. These data indicate that P2X7 activation induces the rapid shedding of
CD23 from primary human and murine B cells and that this process may be mediated by ADAM10.
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Abstract

Activation of the P2X7 receptor by the extracellular damage-associated molecular
pattern, adenosine 5’-triphosphate (ATP), induces the shedding of cell-surface
molecules including the low-affinity IgE receptor, CD23, from human leukocytes. A
disintegrin and metalloprotease (ADAM) 10 mediates P2X7-induced shedding of
CD23 from multiple myeloma RPMI 8226 B cells, but whether this process occurs in
primary B cells is unknown. The aim of the current study was to determine if P2X7
activation induces the rapid shedding of CD23 from primary human and murine B
cells. Flow cytometric and ELISA measurements showed that ATP treatment of
human and murine B cells induced the rapid shedding of CD23. Treatment of cells
with the specific P2X7 antagonist, AZ10606120, near-completely impaired ATPinduced CD23 shedding from both human and murine B cells. ATP-induced CD23
shedding was also impaired in B cells from P2X7 knockout mice. The absence of fulllength, functional P2X7 in the P2X7 knockout mice was confirmed by
immunoblotting of splenic cells, and by flow cytometric measurements of ATPinduced YO-PRO-12+ uptake into splenic B and T cells. The broad-spectrum
metalloprotease antagonist, BB-94, and the ADAM10 antagonist, GI254023X,
impaired P2X7-induced CD23 shedding from both human and murine B cells. This
data indicates that P2X7 activation induces the rapid shedding of CD23 from primary
human and murine B cells and that this process may be mediated by ADAM10.
Key words ADAM10; B lymphocyte; extracellular ATP; IgE receptor; purinergic
receptor
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CD23 is a ‘low affinity’, transmembrane receptor for IgE that is expressed on B cells
and other leukocytes.1 Transmembrane CD23 can be released from the cell-surface to
form soluble CD23, which also binds IgE, and exerts cytokine-like activities on B
cells and other leukocytes.1 Soluble CD23 sustains growth of B cell precursors2,
promotes B and T cell differentiation,3, 4 and drives cytokine release from monocytes5.
The release of CD23 is mediated by membrane metalloproteases of the ADAM (a
disintegrin and metalloprotease) family. ADAM10 is principally responsible for the
constitutive and calcium-induced shedding of CD23.6, 7
Damage-associated molecular patterns (DAMPs) are essential in inflammation and
immunity, and function as signals for cell stress, tissue injury and disease.8
Extracellular adenosine 5’-triphosphate (ATP) is a well-characterised DAMP that
activates the P2X7 receptor, a trimeric cation channel, which plays important roles in
health and disease.9 Activation of P2X7 by extracellular ATP causes the uptake of
organic cations such as ethidium+ and YO-PRO-12+.10 P2X7 activation induces a
number of downstream effects including the shedding of CD23 from human
malignant B cells11,

12

and human dendritic cells13,

14

. Recently our group

demonstrated that P2X7-induced CD23 shedding from the human multiple myeloma
cell line, RPMI 8226, is mediated by ADAM10.15 2’ (3’)-O-(4-Benzoylbenzoyl) ATP
(BzATP)-induced CD23 shedding from murine B cells is also mediated by
ADAM10,16, 17 but a direct role for P2X7 in this process was not established in these
studies. Therefore, it remains unknown if P2X7 activation induces CD23 shedding
from murine B cells, as well as from human B cells. The current study demonstrates
that P2X7 activation induces the rapid shedding of CD23 from primary human and
murine B cells and that this process possibly involves ADAM10.
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Results

P2X7 activation induces rapid CD23 shedding from human B cells
ATP and BzATP at concentrations of 1 mM and 0.3 mM, respectively cause nearmaximal activation of human P2X7.18 Therefore, to first determine if ATP induces
CD23 loss from human B cells, peripheral blood mononuclear cells (PBMCs) were
incubated with 1 mM ATP for up to 30 min and cell-surface expression assessed by
flow cytometry (Figure 1a). ATP induced a rapid loss of cell-surface CD23 from B
cells with a t1/2 of approximately 6 min (Figure 1b).
To determine whether ATP-induced CD23 loss was mediated by P2X7, PBMCs were
incubated for 6 min (the t1/2) in the absence or presence of 1 mM ATP, the most
potent P2X7 agonist 0.3 mM BzATP, or the non-P2X7 agonists 1 mM adenosine
diphosphate (ADP) and uridine 5’-triphosphate (UTP). ATP and BzATP induced a 49
± 9% and 60 ± 9% loss of cell-surface CD23, respectively, while ADP and UTP had
no effect on CD23 expression compared to cells incubated without nucleotide (Figure
1c).
The P2X7 antagonist AZ10606120,19 at a concentration of 100 nM results in nearcomplete inhibition of human P2X7.20 Therefore, to confirm that ATP-induced loss of
CD23 was mediated by P2X7, PBMCs were pre-incubated in the absence or presence
of 100 nM AZ10606120, and 1 mM ATP-induced CD23 loss determined by flow
cytometry. AZ10606120 impaired ATP-induced CD23 loss by 89 ± 12% (Figure 1d).
In the absence of ATP, AZ10606120 did not alter CD23 expression (Figure 1d).
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To determine if the P2X7-induced loss of cell-surface CD23 was due to CD23
shedding, PBMCs were incubated in the absence or presence of 1 mM ATP for 20
min, and the relative amount of soluble CD23 in cell-free supernatants quantified by
ELISA. Incubation of cells with ATP resulted in a significantly higher release of
soluble CD23 compared with cells incubated in the absence of ATP (Figure 1e).
Murine B cells express functional P2X7
The presence of functional P2X7 on primary human B cells is well-established,21 but
less well known for murine B cells. Similar to human P2X7, ATP and BzATP at
concentrations of 1 mM and 0.3 mM, respectively result in near-maximal activation
of murine P2X7.18 While the P2X7 antagonist AZ10606120, at a concentration of 10
µM results in near-complete inhibition of murine P2X7.22 Therefore, to first test
whether functional P2X7 was present on murine B cells from C57BL/6 and DBA/1
mice, splenic cells from these two strains were pre-incubated in the absence or
presence of 10 µM AZ10606120, and 1 mM ATP-induced YO-PRO-12+ uptake into B
cells determined by flow cytometry. C57BL/6 mice were studied because of the
availability of the Pfizer P2X7 knockout mice,23 which had been backcrossed onto a
C57BL/6 background.24 DBA/1 mice were also studied as this strain has been used to
demonstrate a role for CD23 in rheumatoid arthritis25, a disease in which P2X7 is also
thought to be involved.26, 27 ATP-induced significant YO-PRO-12+ uptake into murine
B cells, from either C57BL/6 or DBA/1 mice, compared to YO-PRO-12+ uptake in the
absence of ATP (Figure 2a, b). Moreover, 10 µM AZ10606120 significantly impaired
ATP-induced YO-PRO-12+ uptake in B cells from C57BL/6 or DBA/1 mice, by 88 ±
14% or 95 ± 8%, respectively (Figure 2a, b). In the absence of ATP, AZ10606120 did
not alter YO-PRO-12+ uptake in B cells from either mouse strain (Figure 2a, b).
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P2X7 activation induces rapid CD23 shedding from murine B cells
To determine if ATP induces CD23 loss from murine B cells, splenic cells were
incubated with 1 mM ATP for up to 30 min and cell-surface CD23 expression
assessed by flow cytometry (Figure 3a, b). ATP induced a rapid loss of cell-surface
CD23 from B cells from both C57BL/6 and DBA/1 mice with a t1/2 of approximately
7 min (Figure 3c).
To determine if ATP-induced CD23 loss was mediated by P2X7, cells from both
mouse strains were incubated for 7 min (the t1/2) in the absence or presence of 1 mM
ATP, 0.3 mM BzATP, 1 mM ADP or 1 mM UTP. Similar to above (Figure 3c), ATP
induced a 37 ± 4% and 57 ± 4% loss of cell-surface CD23 in B cells from C57BL/6
and DBA/1 mice, respectively (Figure 3d, e). BzATP induced a 33 ± 8% and 58 ± 5%
loss of cell-surface CD23 in B cells from C57BL/6 and DBA/1 mice, respectively,
while ADP and UTP had no effect compared to cells incubated without nucleotide in
either mouse strain (Figure 3d, e).
To confirm that ATP-induced loss of CD23 was mediated by P2X7, cells were preincubated in the absence or presence of 10 µM AZ10606120, and 1 mM ATP-induced
CD23 loss determined by flow cytometry. AZ10606120 impaired ATP-induced CD23
loss by 95 ± 8% and 97 ± 6% in B cells from C57BL/6 and DBA/1 mice respectively
(Figure 3f, g). In the absence of ATP, AZ10606120 did not alter CD23 expression in
B cells from either mouse strain (Figure 3f, g).
Finally, to further confirm a role for P2X7 in ATP-induced CD23 loss, P2X7
knockout mice were used. Flow cytometric measurements demonstrated that the
amount of CD23 expression between control-treated B cells from wild-type and P2X7
knockout mice was similar (Figure 3h). In contrast, incubation with 1 mM ATP
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induced a loss of cell-surface CD23 in B cells from wild-type mice (34 ± 10% loss)
but ATP-induced CD23 loss from B cells from P2X7 knockout mice was minimal (8
± 7% loss) (Figure 3h).
To indirectly assess if the ATP-induced loss of CD23 from murine B cells was a
result of CD23 shedding or internalisation, splenic cells from C57BL/6 mice were
incubated in the absence or presence of 1 mM ATP for 20 min and the expression of
cell-surface CD23 on fixed cells, or total CD23 in fixed and permeabilised cells was
examined by flow cytometry. CD23 expression was similar in fixed cells compared to
fixed and permeabilised cells (Figure 4a) suggesting that the P2X7-induced loss of
CD23 was due to CD23 shedding rather than internalisation.
To directly determine if the P2X7-induced loss of cell-surface CD23 was due to
CD23 shedding, splenic cells from C57BL/6 wild-type and P2X7 knockout mice were
incubated in the absence or presence of 1 mM ATP for 20 min, and the relative
amount of soluble CD23 in cell-free supernatants quantified by ELISA. Incubation of
wild-type cells with ATP resulted in a significantly higher release of soluble CD23
compared with P2X7 knockout cells incubated with ATP, or cells of either strain
incubated in the absence of ATP (Figure 4b). Moreover, the amount of soluble CD23
release from P2X7 knockout cells incubated in the absence or presence of ATP was
similar to that of wild-type cells incubated in the absence of ATP (Figure 4b).
Splenic cells from P2X7 knockout mice do not express full-length, functional
P2X7
Recent evidence indicates that Pfizer P2X7 knockout mice,23 from which the P2X7
knockout mice in the current study were derived,24 express three novel C-terminal
truncated P2X7 variants termed 13A (~60 kDa), 13B (~60 kDa) and hybrid (~70 kDa)
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P2X7.28 Pfizer P2X7 knockout mice were generated by targeting exon 13 of the
P2RX7 gene,23 and PCR with primers to exons 9 and 11 of the P2RX7 gene
demonstrates P2X7 expression in various tissues from these mice.28 Consistent with
these findings, quantitative RT-PCR with primers to exons 1 and 2 of the P2RX7 gene
revealed significant expression of P2RX7 transcripts in the splenic cells from both
wild-type and P2X7 knockout mice (Figure 5a). Relative P2X7 expression was 2-fold
higher in P2X7 knockout splenic cells compared to wild-type splenic cells but this
failed to reach statistical significance (Figure 5a). This data indicates the potential
presence of escape variants of P2X7 in the P2X7 knockout mice used to study ATPinduced CD23 shedding above.
To determine if the mRNA transcripts for P2X7 detected above (Figure 5a) were
translated into protein, splenic cells of these mice were examined by immunoblotting
with an antibody against the extracellular domain of murine P2X7, which can detect
full-length P2X7, as well as the C-terminal truncated P2X7 variants.28 Murine RAW
264.7 macrophages, which are known to express full-length P2X7,29 were included as
a positive control. Immunoblotting identified a major band at 81 kDa, corresponding
to glycosylated full-length P2X7, in wild-type splenic cells and RAW 264.7
macrophages, but not in P2X7 knockout splenic cells (Figure 5b). Immunoblotting
also revealed a major band at 75 kDa in all three cell types (Figure 5b). The size of
this band corresponds to that of the hybrid C-terminal truncated P2X7 variant present
in Pfizer P2X7 knockout mice. However, this variant contains a short sequence of the
targeting vector originally used to disrupt the P2RX7 gene,28 thus this variant cannot
be present in wild-type splenic cells or RAW 264.7 macrophages. Therefore, this 75
kDa band most likely represents non-specific binding. Immunoblotting also detected a
major band at 154 kDa in wild-type and P2X7 knockout splenic cells, but not in
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RAW264.7 macrophages (Figure 5b). This band does not correspond to any known
P2X7 variant and thus most likely represents non-specific binding.
Flow cytometric measurements of ATP-induced YO-PRO-12+ uptake were then used
to confirm the absence of functional P2X7 in splenic B cells from the P2X7 knockout
mice used to study ATP-induced CD23 shedding above. T cells from
GlaxoSmithKline P2X7 knockout mice, derived by targeting exon 1 of the P2RX7
gene,30 express P2X7k, an alternate splice variant that has escaped gene inactivation
and encodes functional receptors.31-33 Therefore, ATP-induced YO-PRO-12+ uptake
into splenic T cells was also assessed. As expected, 1 mM ATP induced YO-PRO-12+
uptake into both B and T cells from wild-type mice (Figure 5c). In contrast, 1 mM
ATP failed to induce YO-PRO-12+ uptake into either B or T cells from P2X7
knockout mice (Figure 5c). Collectively, these results indicate that the P2X7 knockout
mice used to study ATP-induced CD23 shedding above do not express full-length,
functional P2X7.
ADAM10 mediates P2X7-induced CD23 shedding from human and murine B
cells
To determine a role for metalloproteases in P2X7-induced CD23 shedding, human
PBMCs or murine splenic cells were pre-incubated in the absence or presence of the
broad-spectrum metalloprotease antagonist, BB-94,34 or the ADAM10 antagonist,
GI254023X,35 and 1 mM ATP-induced CD23 shedding from B cells determined by
flow cytometry. BB-94 (1 µM) impaired P2X7-induced CD23 shedding from B cells
by 66 ± 10%, 100 ± 0% and 96 ± 6% from human, C57BL/6 and DBA/1 mice,
respectively (Figure 6a-c). GI254023X (3 µM) impaired P2X7-induced CD23
shedding from B cells by 77 ± 20%, 83 ± 29% and 100 ± 0% from human, C57BL/6
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and DBA/1 mice respectively (Figure 6d-f). In the absence of ATP, BB-94 did not
alter basal CD23 expression in human and murine cells (Figure 6a-c). Likewise,
GI254023X did not alter basal CD23 expression in human or DBA/1 B cells (Figure
6d, f). In contrast, GI254023X significantly reduced basal (constitutive) CD23
shedding from C57BL/6 B cells (Figure 6e).

Discussion

The current study, shows for the first time that P2X7 activation induces the rapid
shedding of CD23 from primary human and murine B cells. This was confirmed by a
series of experiments. First, ATP induced the rapid cell-surface loss of CD23
shedding with a t1/2 of approximately 6 and 7 min from human and murine B cells,
respectively. Second, the most potent P2X7 agonist BzATP also induced the rapid
cell-surface loss of CD23, whereas the non-agonists ADP and UTP had no effect.
Third, a specific P2X7 antagonist, AZ10606120,19 almost completely impaired ATPinduced CD23 shedding in both human and murine B cells. Fourth, ATP failed to
induce CD23 shedding from B cells from C57BL/6 P2X7 knockout mice. Finally,
measurements of soluble CD23 (as well as total CD23 expression for murine B cells)
indicated that cell-surface loss of CD23 was due to shedding from both human and
murine B cells.
Using the ADAM10 inhibitor, GI254023X,35 the current study also shows that P2X7induced CD23 shedding from human and murine B cells is possibly mediated, at least
in part, by ADAM10. This finding is consistent with a role for ADAM10 in P2X7-
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induced CD23 shedding from human RPMI 8226 myeloma cells.15 Remarkably, the
rate of P2X7-induced CD23 shedding from human and murine B cells was similar to
that observed for RPMI 8226 cells (t1/2 of ~7 min) indirectly supporting the
involvement of a common mechanism. A potential role for ADAM10 in P2X7induced CD23 shedding from primary B cells is indirectly supported by other studies.
ATP-induced CD23 shedding from human leukaemic monocytic U937 cells7, and
BzATP-induced CD23 shedding from Chinese hamster ovary cells16 and murine B
cells17, are also mediated by ADAM10. The possibility remains that other
metalloproteases may also be involved in P2X7-induced CD23 shedding from human
and murine B cells. ADAM 8, 15, 28 and 33 have been associated with constitutive
CD23 shedding from CD23-transfected HEK293 cells36 and primary murine
embryonic fibroblasts6, although ADAM10 was identified as the principal sheddase of
CD23.6
It remains unknown how P2X7 potentially activates ADAM10. Repeated attempts
using a Fluorogenic Peptide Substrate III assay (R&D Systems, Minneapolis, MN)
(which detects the activity of ADAM10, as well as ADAM8, 9 and 17) were unable to
demonstrate that ATP could stimulate ADAM10 activation on RPMI 8226 cells
despite detectable ADAM activity on these cells in the absence of ATP (Pupovac and
Sluyter, unpublished observations). Thus, the possibility remains that P2X7 activation
induces cell-surface CD23 shedding through the co-localisation of ADAM10 and
CD23, rather than by directly stimulating ADAM10 activity. Finally, using a
candidate approach, our previous studies also failed to identify potential intracellular
signalling molecules involved in P2X7-induced CD23 shedding.20
The current study demonstrates the presence of functional P2X7 on murine B cells
from both C57BL/6 and DBA/1 mice. Although the presence of functional P2X7 on
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human B cells is well established, reports of functional P2X7 on murine B cells are
limited. In the current study, P2X7 activation induced CD23 shedding from murine B
cells. Moreover, ATP was shown to induce YO-PRO-12+ uptake into murine B cells,
and that the process was impaired by AZ10606120 and in B cells from P2X7
knockout mice. Of note, the relative amounts of P2X7-mediated YO-PRO-12+ uptake
and rates of P2X7-mediated CD23 shedding were similar between C57BL/6 and
DBA/1 mice. This similar amount of relative P2X7 function most likely reflects the
presence of the partial loss-of-function mutation P451L in both of these strains.37
A previous study has shown that LPS can induce CD23 shedding from human and
murine B cells, and that this process is mediated by Toll-like receptor 4 (TLR4) and
matrix metalloprotease 9.38 However it remains unlikely that LPS, potentially present
in the reagents used, was responsible for the ATP-induced CD23 observed in the
current study. First, ATP induced the rapid (<30 min) shedding of CD23; in contrast
LPS induces the slow (24 h) shedding of CD23.38 Second, ADP and UTP failed to
induce CD23 shedding, while ATP-induced shedding was impaired by P2X7
antagonists and in B cells from P2X7 knockout mice. Nevertheless, future studies
using B cells from either C3H/HeJ mice, which are hyporesponsive to LPS due to
single point mutation in the TLR4 gene,39 or TLR4 knockout mice will be of value to
address this potential issue further.
Human genetic27,

40

and murine model studies26,

41

suggest a role for P2X7 in

rheumatoid arthritis and Sjogren’s syndrome. The role of P2X7 in these disorders has
largely been attributed to the release of the proinflammatory cytokines, interleukin-1β
and interleukin-18.26, 42 However, synovial or circulating soluble CD23 is elevated in
patients with rheumatoid arthritis43, 44 or Sjogren’s syndrome45. Moreover, B cells also
play major roles in the pathogenesis of these disorders through the production of
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autoantibodies.46, 47 Thus, the possibility remains that P2X7-induced shedding of proinflammatory soluble CD23 from B cells may also be involved in rheumatoid
arthritis, Sjogren’s syndrome or other disorders. However, evidence directly linking B
cells, P2X7 and CD23 in inflammatory and autoimmune disease is lacking. An
alternate, but not mutually exclusive possibility is that ATP-induced CD23 shedding
is an early event of P2X7-mediated apoptosis. In the current study, 30 min incubation
with ATP caused a small but significant amount of apoptosis, determined by forward
scatter (cell shrinkage) and 7AAD uptake (loss of membrane integrity),48 in murine
but not human B cells compared to respective B cells incubated in the absence of ATP
(results not shown). In contrast, human and murine B cell apoptosis was not increased
following 6-7 min treatment with either ATP or BzATP compared to control
treatment, nor was B cell apoptosis increased following incubation with AZ10606120
in the absence or presence of ATP (results not shown). Nevertheless given that P2X7
activation can induce apoptosis in human PBMCs49 and murine splenic cells,50 the
possibility remains that ATP-induced CD23 shedding is an early upstream event in
P2X7-mediated apoptosis of B cells.
In conclusion, this study demonstrates human and murine P2X7 activation induces the
rapid shedding of CD23 from B cells. Moreover, the study indicates a potential role
for ADAM10 in this process.
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Methods

Reagents
Ficoll PaqueTM PLUS was from GE Healthcare Bio-Sciences (Uppsala, Sweden).
DMEM/F12 medium, YO-PRO-1 iodide, TRIzol reagent, and TaqMan Universal
Master Mix II with uracil-DNA glycosylase (UDG) and Gene Expression Assays
were from Life Technologies (Grand Island, NY). Red blood cell lysis buffer, ATP,
BzATP, ADP, UTP, paraformaldehyde and RNAlater were from Sigma-Aldrich (St.
Louis, MO). Dimethyl sulphoxide (DMSO) and Tween-20 were from Amresco
(Solon, OH). AZ10606120 and BB-94 (Batimastat) were from Tocris Bioscience
(Ellisville, MO). GI254023X was kindly provided by GlaxoSmithKline (Stevenage,
United Kingdom). 7-Aminoactinomycin D (7AAD) was from Enzo Life Sciences
(Plymouth Meeting, PA). Phycoerythrin (PE)-conjugated murine anti-human CD23
(clone EBVCS2), PE-conjugated isotype control (clone P3.6.2.8.1), fluorescein
isothiocyanate (FITC)-conjugated rat anti-murine CD23 (clone B3B4), FITCconjugated isotype control (clone eBR2a), allophycocyanin (APC)-conjugated murine
anti-human CD19 (clone HIB19) and APC-conjugated rat anti-murine CD19 (clone
eBio1D3) monoclonal antibodies (mAb) were from eBioscience (San Diego, CA).
Peridinin chlorophyll protein/cyanine 5.5 (PerCP/Cy5.5)-conjugated hamster antimurine CD3 (clone 145-2C11) mAb was from BioLegend (San Diego, CA). Rabbit
anti-murine P2X7 polyclonal antibody (extracellular domain) was from Alomone
Labs (Jerusalem, Israel).
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Cells
All experiments involving humans and mice were approved by the University of
Wollongong ethics committee. Human peripheral blood was collected into
VACUETTE® lithium heparin tubes (Greiner Bio-One, Frickenhausen, Germany) and
diluted with an equal volume of phosphate buffered saline (PBS). PBMCs were
separated by density gradient centrifugation over Ficoll-PaqueTM PLUS (560 x g for
30 min), washed once in PBS (450 x g for 10 min) and then twice in NaCl medium
(145 mM NaCl, 5 mM KCl, 5 mM glucose, 10 mM HEPES, pH 7.4). The mean
percentage of CD19+ cells within the 13 PBMC preparations used was 4.0% (range
2.5-7.5%). C57BL/6 and DBA/1 mice were from Animal Resources Centre (Perth,
Australia) or Australian BioResources (Moss Vale, Australia). P2X7 knockout mice23
backcrossed onto a C57BL/6 background, were bred at the Centenary Institute
(Sydney, Australia) or the University of Wollongong (Wollongong, Australia).24 Mice
were euthanised and spleens collected in ice-cold PBS. Spleens were teased apart
using a needle and forceps in ice-cold PBS, and cells were filtered through a 70 µm
nylon cell strainer (BD, San Jose, CA). Splenic cells were then washed in ice-cold
PBS (400 x g for 5 min) and the pellet resuspended in red blood cell lysis buffer. Red
blood cells were lysed for 3 min at room temperature with agitation and the remaining
leukocytes were washed once with ice-cold DMEM/F12 medium. Cells were then
washed twice in NaCl medium (for functional assays) or PBS (for PCR or
immunoblotting). Murine RAW 264.7 macrophages (American Type Culture
Collection, Manassas, VA) were maintained as described.24
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Measurement of nucleotide-induced CD23 shedding by flow cytometry
Nucleotide-induced CD23 shedding from cells was indirectly assessed by flow
cytometric measurements of ATP-induced loss of cell-surface CD23 as described.11
Briefly, PBMCs or splenic cells suspended in NaCl medium (1 x 106 cells/ml), were
incubated in the absence or presence of nucleotide (as indicated) for up to 30 min at
37ºC. In some experiments, cells in NaCl medium were pre-incubated at 37°C for 15
min in the absence or presence of antagonist, and then in the absence or presence of 1
mM ATP (as indicated). Incubations with nucleotide were stopped by addition of an
equal volume of ice-cold MgCl2 medium (NaCl medium containing 20 mM MgCl2)
and centrifugation. Cells were then washed once with NaCl medium and incubated
with species-specific fluorochrome-conjugated anti-CD23 or isotype control mAb,
anti-CD19 mAb and 7AAD for 30 min at 4ºC. The mean fluorescence intensity (MFI)
of cell-surface CD23 expression on viable CD19+7AAD- cells was determined using a
BD LSR II flow cytometer (using band-pass filters 575/26 or 515/20 nm for CD23,
660/20 nm for CD19 and 695/40 nm for 7AAD) and FlowJo software (Tree Star,
Ashland, OR).
Cell-surface and total CD23 expression following treatment was compared as
previously described.51 Splenic cells were washed once with NaCl medium and
labelled with APC-conjugated anti-murine CD19 and 7AAD for 30 min at 4ºC. Cells
were fixed by suspension in ice-cold 0.25% paraformaldehyde in PBS for 1 hour at
4°C. Cells were then either washed once in cold PBS (fixed) or in 0.2% Tween-20 in
PBS (fixed and permeabilised) and labelled with FITC-conjugated anti-murine CD23
or isotype control mAb for 30 min at 4°C. The MFI of cell-surface and total (cellsurface and intracellular) CD23 expression on CD19+ cells was determined using flow
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cytometry (using band-pass filters 515/20 nm for CD23, 660/20 nm for CD19 and
695/40 nm for 7AAD) and FlowJo software.
Measurement of soluble CD23 by ELISA
PBMCs or splenic cells suspended in NaCl medium (5 x 106 cells/ml), were incubated
in the absence or presence of 1 mM ATP for 20 min at 37°C. Incubations were
stopped by centrifugation (11000 x g for 10 s). Cell-free supernatants were stored at 80°C until required. Soluble CD23 was quantified using the Human CD23/Fcε RII
Quantikine ELISA Kit or the Mouse CD23/Fcε RII DuoSet ELISA Development Kit
(both R&D Systems), according to the manufacturer’s instructions.
Measurement of P2X7 pore formation by flow cytometry
P2X7-induced pore formation in murine B cells was assessed by flow cytometric
measurements of ATP-induced YO-PRO-12+ uptake as described.52 Briefly, splenic
cells suspended in NaCl medium (1 x 106 cells/ml) were pre-incubated in the absence
or presence of 10 µM AZ10606120 (as indicated), and then with 1 µM YO-PRO-12+
in the absence or presence of ATP (as indicated) for 15 min at 37°C. Incubations were
stopped by addition of an equal volume of ice-cold MgCl2 medium and centrifugation.
Cells were washed once with NaCl medium. Cells were labelled with APCconjugated anti-murine CD19 mAb (and in some experiments, also with
PerCP/Cy5.5-conjugated anti-murine CD3 mAb) and washed once with NaCl
medium. The MFI of YO-PRO-12+ uptake into CD19+ cells (or in some experiments,
CD19+CD3- or CD19-CD3+ cells) was determined using flow cytometry (using bandpass filters 515/20 nm for YO-PRO-12+, 695/40 nm for CD3 and 660/20 nm for
CD19) and FlowJo software.
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Measurement of P2X7 by quantitative real time-PCR
Mouse spleens were stored in RNAlater at -20°C until required. Total RNA was
isolated using TRIzol reagent according to the manufacturer’s instructions. cDNA
synthesis was performed using a qScript cDNA Synthesis Kit (Quanta Biosciences,
Gaithersburg, MD) following the manufacturer’s instructions. Real-time PCR
reactions consisted of 5 µL 2X TaqMan Universal Master Mix II with UDG, 0.5 µL
of 20X TaqMan Gene Expression Assay (specific primers/probes), 2 µL cDNA and
sterile water in a total volume of 10 µL. Each PCR reaction was performed in
triplicate. Quantitative real-time PCR was performed using standard primers for
murine P2RX7 (FAM-labelled; Mm00440578_m1) and murine GAPDH (VIClabelled; Mm99999915_g1). Real-time PCR was performed on an Eco Real-time PCR
System (Illumina, San Diego, CA) in sealed 48-well plates (Gene Target Solutions,
Dural, Australia). The PCR cycle consisted of an initial UDG incubation step of 50°C
for 2 min, polymerase activation step of 95°C for 10 min and 40 cycles of 95°C for 15
s and 60°C for 1 min. Relative gene expression was normalised to the murine
GAPDH housekeeping gene and determined using Eco Software v5.0 (Illumina).
Measurement of P2X7 by immunoblotting
Immunoblotting of murine cells was performed as described.53 Briefly, whole cell
lysates were separated under reducing conditions using Any kD Mini-PROTEAN
TGX Stain-Free Gels (Bio-Rad, Hercules, CA) and transferred to nitrocellulose
membrane (Bio-Rad), and immunoblotting was performed using an anti-P2X7
antibody. To confirm equal protein loading between splenic cell samples within stainfree gels, total protein was assessed using a Bio-Rad Criterion Stain Free Imager
(results not shown).
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Presentation of data and statistics
Data is presented as mean ± SD from individual people or mice except where stated.
Differences between groups were compared using an unpaired Student’s t-test for
single comparisons or one-way ANOVA (using Tukey’s multiple comparison test)
except for human ELISA data, for which a paired Student’s t-test was used. Statistical
comparisons were performed using Prism 5 (Windows version 5.01; GraphPad
Software, San Diego, CA) with P < 0.05 considered significant.
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Figure 1 P2X7 activation induces CD23 shedding from human B cells. (a, b) PBMCs
in NaCl medium were incubated for up to 30 min at 37°C in the absence or presence
of 1 mM ATP as indicated. (c) Cells in NaCl medium were incubated in the absence
(basal) or presence of 1 mM ATP, 0.3 mM BzATP, 1 mM ADP or 1 mM UTP at
37°C for 6 min. (d) PBMCs in NaCl medium were preincubated at 37°C for 15 min in
the absence or presence of 100 nM AZ10606120 (AZ) and then in the absence (basal)
or presence of 1 mM ATP for 6 min at 37°C. (a-d) Incubations were stopped by
addition of MgCl2 medium and centrifugation. PBMCs were labelled with APCconjugated anti-CD19, PE-conjugated anti-CD23 or isotype control mAb and 7AAD.
The mean fluorescence intensity of cell-surface CD23 expression on CD19+7AAD- B
cells was determined by flow cytometry. (e) PBMCs in NaCl medium were incubated
in the absence (basal) or presence of 1 mM ATP at 37°C for 20 min, incubations were
stopped by centrifugation and the amount of soluble CD23 in cell-free supernatants
determined by ELISA. (a) Histograms (from one representative individual) show
CD23 expression on (black or grey fill) or isotype control mAb binding (black line) to
CD19+7AAD- PBMCs incubated in the absence (black fill or black line) or presence
(grey fill) of 1 mM ATP for 30 min; isotype control mAb binding to CD19+7AADPBMCs incubated in the presence of ATP was similar to that of cells incubated in the
absence of ATP (not shown). (b-e) Results are mean ± SD (3 individuals); *P < 0.05
and **P < 0.01 compared to basal, and †P < 0.05 compared to ATP alone.

Figure 2 C57BL/6 and DBA/1 murine B cells express functional P2X7. (a, b) Splenic
cells in NaCl medium were pre-incubated in the absence or presence of 10 µM
AZ10606120 at 37°C for 15 min. Cells were then incubated with 1 µM YO-PRO-12+
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in the absence (basal) or presence of 1 mM ATP at 37°C for 15 min. Incubations were
stopped by the addition of MgCl2 medium and centrifugation. Cells were labelled
with APC-conjugated anti-CD19 and 7AAD, and the mean fluorescence intensity of
YO-PRO-12+ uptake on CD19+7AAD- B cells was determined by flow cytometry.
Results are mean ± SD ((a) 3 mice, or (b) duplicate values from 2 mice); **P < 0.01
compared to control, and ††P < 0.01 compared to ATP alone.

Figure 3 P2X7 activation induces CD23 shedding from B cells from C57BL/6 and
DBA/1 mice. (a-c) Splenic cells in NaCl medium were incubated for up to 30 min at
37°C in the absence or presence of 1 mM ATP as indicated. (d, e) Splenic cells in
NaCl medium were incubated in the absence (basal) or presence of 1 mM ATP, 0.3
mM BzATP, 1 mM ADP or 1 mM UTP at 37°C for 7 min. (f, g) Splenic cells in NaCl
medium were preincubated at 37°C for 15 min in the absence or presence of 10 µM
AZ10606120 (AZ) and then in the absence (basal) or presence of 1 mM ATP for 7
min at 37°C. (h) Splenic cells from wild-type (WT) or P2X7 knockout (KO) C57BL/6
mice in NaCl medium were incubated in the absence (basal) or presence of 1 mM
ATP for 20 min at 37°C. (a-h) Incubations were stopped by addition of MgCl2
medium and centrifugation. Cells were labelled with APC-conjugated anti-CD19,
FITC-conjugated anti-CD23, or isotype control mAb and 7AAD. (a, b) Histograms
(from one representative (a) C57BL/6 or (b) DBA/1 mouse) show CD23 expression
on (black or grey fill) or isotype control mAb binding (black line) to CD19+7AADPBMCs incubated in the absence (black fill or black line) or presence (grey fill) of 1
mM ATP for 30 min; isotype control mAb binding to CD19+7AAD- splenic cells
incubated in the presence of ATP was similar to that of cells incubated in the absence
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of ATP (not shown). (c-h) The mean fluorescence intensity of CD23 expression on
CD19+7AAD- B cells was determined by flow cytometry. Results are mean ± SD ((c,
f) triplicate values from 1 mouse or (d, e, g, h) 3 mice); *P < 0.05 and

**

P < 0.01

compared to control, and ††P < 0.01 compared to ATP alone.

Figure 4 P2X7 activation induces CD23 shedding from B cells from C57BL/6 mice.
(a, b) Splenic cells from wild-type (WT) or (b) P2X7 knockout (KO) C57BL/6 mice
in NaCl medium were incubated for 20 min at 37°C in the absence (basal) or presence
of 1 mM ATP. (a) Incubations were stopped by addition of MgCl2 medium and
centrifugation. Cells were labelled with APC-conjugated anti-CD19 mAb and 7AAD,
and fixed with paraformaldehyde in PBS. Fixed cells were then labelled with FITCconjugated anti-CD23 or isotype control mAb in the absence (fixed, F) or presence
(fixed and permeabilised, F & P) of Tween-20 in PBS. The mean fluorescence
intensity of CD23 expression in CD19+7AAD- B cells was determined by flow
cytometry. (b) Incubations were stopped by centrifugation and the amount of soluble
CD23 in cell-free supernatants determined by ELISA. Results are mean ± SD ((a) 3 or
(b) 4 mice); **P < 0.01 compared to control, and ††P < 0.01 compared to ATP.

Figure 5 Splenic cells from P2X7 knockout mice do not express full-length,
functional P2X7. (a) Relative P2X7 expression in the spleens of wild-type (WT) and
P2X7 knockout (KO) C57BL/6 mice was measured by quantitative real time-PCR
using primers to exons 1 and 2 of the P2RX7 gene. (b) Whole lysates of WT and
P2X7 KO splenic cells, and RAW 264.7 macrophages (RAW) were examined by
immunoblotting using an antibody agonist the extracellular epitope of P2X7. (c)
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Splenic cells, from WT and P2X7 KO mice, in NaCl medium were incubated with 1
µM YO-PRO-12+ in the absence or presence of 1 mM ATP at 37°C for 15 min.
Incubations were stopped by the addition of MgCl2 medium and centrifugation. Cells
were labelled with PerCP/Cy5.5-conjugated anti-CD3 mAb and APC-conjugated antiCD19 mAb, and the mean fluorescence intensity of YO-PRO-12+ uptake into CD3CD19+ B cells and CD3+CD19- T cells was determined by flow cytometry. Results
are (a, c) mean ± SD (3 mice; points represent individual mice) or (b) one
representative of 2 experiments.

Figure 6 Metalloproteases mediate P2X7-induced shedding from human and murine
B cells. (a, d) Human peripheral blood mononuclear cells, and (b, e) C57BL/6 or (c, f)
DBA/1 murine splenic cells were preincubated in the presence of (a-f) DMSO, (a-c) 1
µM BB-94 (BB) or (d-f) 3 µM GI254023X (GI), and (a-f) then in the absence (basal)
or presence of 1 mM ATP at 37°C for 7 min. Incubations were stopped by addition of
MgCl2 medium and centrifugation. B cells were labelled with APC-conjugated antiCD19 mAb, PE- or FITC-conjugated anti-CD23, or isotype control mAb and 7AAD.
The mean fluorescence intensity of cell-surface CD23 expression on CD19+7AAD- B
cells was determined by flow cytometry. Results are mean ± SD ((a) 4 or (d) 3
individuals, or (b, c, e, f) 3 mice); *P < 0.05 and **P < 0.01 compared to control, and
††

P < 0.01 compared to ATP alone.
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